Relapsed/Refractory Primary Central Nervous System Lymphoma Clinical Trials

4 clinical trials for Relapsed/Refractory Primary Central Nervous System Lymphoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma — RECRUITING · PHASE3
• IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) — RECRUITING · PHASE3
• A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma — RECRUITING · PHASE1
• Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma — SUSPENDED · PHASE1

Refine this search